Phase I trial of using a prostatic urethral lift implant with stereotactic ablative body radiotherapy for men with prostate cancer and benign prostatic hyperplasia (NCT05311527)

Abstract Background Prostatic urethral lift (PUL), an established minimally invasive surgical intervention for benign prostatic hyperplasia (BPH), may serve as a strategy to alleviate obstructive symptoms and to broaden eligibility for stereotactic ablative body radiotherapy (SAbR). We evaluated the safety and feasibility of combining PUL, spacer gel, fiducial markers, and SAbR for men with prostate cancer (PCa) who have underlying obstructive urinary symptoms due to BPH. Materials/methods This phase I, non-blinded, single-arm clinical trial included men with intermediate-risk PCa with symptomatic BPH with the American Urological Association Symptom Score (AUASS) ≥ 17. PUL, rectoprostatic spacer gel and fiducial markers were placed during a single procedure under general anesthesia. Subjects subsequently underwent SAbR to a dose of 4000 cGy in 5 fractions to the prostate and proximal seminal vesicles. Results Among the 15 enrolled study participants, four individuals experienced Clavien–Dindo grade 1–2 perioperative complications related to PUL implantation. In addition, eight patients experienced CTCAE v5.0 grade 1–2 genitourinary adverse events during or following SAbR. No grade ≥3 toxicities occurred. Mean AUASS significantly improved from 22.1 to 14.0 at 3 months post-SAbR ( p < 0.01). Mean EPIC urinary obstructive/irritative scores improved over time from 64.6 to 81.3 ( p = 0.02), and patients reached peak flow faster at 3 months post-SAbR ( p = 0.03). Conclusions PUL with spacer gel, followed by SAbR, appears to be a safe and feasible strategy for PCa patients with underlying BPH. While waiting for a longer-term follow-up, we observed a modest improvement in obstructive urinary symptoms at 3 months post-radiation.

Authors

Publication Details

Journal
Prostate Cancer and Prostatic Diseases
Published
2026-11-16
DOI
https://doi.org/10.1038/s41391-026-01169-6
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Phase I trial of using a prostatic urethral lift implant with stereotactic ablative body radiotherapy for men with prostate cancer and benign prostatic hyperplasia (NCT05311527)

Raquibul Hannan, Jennifer W. Tse, Young Suk Kwon, Tamara Dickinson et al.
Prostate Cancer and Prostatic Diseases
Prostate Cancer Diagnosis and Treatment
article

Phase I trial of using a prostatic urethral lift implant with stereotactic ablative body radiotherapy for men with prostate cancer and benign prostatic hyperplasia (NCT05311527)

Raquibul Hannan, Jennifer W. Tse, Young Suk Kwon, Tamara Dickinson, Shaghayegh Rezaie, Yesenia Gonzalez, Kris E. Gaston, Robert D Timmerman, Aurélie Garant, Brad J. Hornberger, Neil Bipinchandra Desai, Ryan J. Mauck, MinJae Lee, Claus Roehrborn, Reena Kudchadker, Howard Morgan, Maricruz Ibarra, Solomon Woldu, Daniel Yang, Yang Kyun Park
article en

Abstract

Abstract Background Prostatic urethral lift (PUL), an established minimally invasive surgical intervention for benign prostatic hyperplasia (BPH), may serve as a strategy to alleviate obstructive symptoms and to broaden eligibility for stereotactic ablative body radiotherapy (SAbR). We evaluated the safety and feasibility of combining PUL, spacer gel, fiducial markers, and SAbR for men with prostate cancer (PCa) who have underlying obstructive urinary symptoms due to BPH. Materials/methods This phase I, non-blinded, single-arm clinical trial included men with intermediate-risk PCa with symptomatic BPH with the American Urological Association Symptom Score (AUASS) ≥ 17. PUL, rectoprostatic spacer gel and fiducial markers were placed during a single procedure under general anesthesia. Subjects subsequently underwent SAbR to a dose of 4000 cGy in 5 fractions to the prostate and proximal seminal vesicles. Results Among the 15 enrolled study participants, four individuals experienced Clavien–Dindo grade 1–2 perioperative complications related to PUL implantation. In addition, eight patients experienced CTCAE v5.0 grade 1–2 genitourinary adverse events during or following SAbR. No grade ≥3 toxicities occurred. Mean AUASS significantly improved from 22.1 to 14.0 at 3 months post-SAbR ( p < 0.01). Mean EPIC urinary obstructive/irritative scores improved over time from 64.6 to 81.3 ( p = 0.02), and patients reached peak flow faster at 3 months post-SAbR ( p = 0.03). Conclusions PUL with spacer gel, followed by SAbR, appears to be a safe and feasible strategy for PCa patients with underlying BPH. While waiting for a longer-term follow-up, we observed a modest improvement in obstructive urinary symptoms at 3 months post-radiation.

Prostate Cancer and Prostatic Diseases
Prostate Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon